Garry E. Menzel

Insider Reports History

Identity Names, identifiers, and filing context for this profile. 1 identity field
Reporting-owner location
Bedford, MA
SEC source record Original filing metadata and source links for verification. 1 source field
Latest reporting-owner signature
/s/ Brent Hatzis-Schoch, Attorney-in-Fact
Source: Latest parsed Forms 3/4/5 signature
Source evidence Original filing metadata and source links for verification. 1 source field
Transaction source note
Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.

Reported holdings for Garry E. Menzel

Form 4 holding Director

Adaptimmune Therapeutics PLC

Security class
American Depositary Shares representing Ordinary Shares
Shares / value
75,056
Estimated value
$50,513
Report date
10 Jul 2023
Price
$0.6730
Ownership
Direct
Form 4 holding Director

Adaptimmune Therapeutics PLC

Security class
Option to purchase Ordinary Shares
Shares / value
1,121,604
Estimated value
Report date
01 Jul 2024
Price
Ownership
Direct
Underlying class
Ordinary Shares
Underlying amount
Form 4 holding Director

Stoke Therapeutics, Inc.

Security class
Director Stock Option (Right to Buy)
Shares / value
29,747
Estimated value
Report date
03 Jun 2025
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President and CEO, Director

TCR2 THERAPEUTICS INC.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
01 Jun 2023
Price
$1.72
Ownership
Direct
Form 4 holding President and CEO, Director

TCR2 THERAPEUTICS INC.

Security class
Common Stock
Shares / value
0
Estimated value
Report date
01 Jun 2023
Price
$1.72
Ownership
Indirect
Form 4 holding President and CEO, Director

TCR2 THERAPEUTICS INC.

Security class
Restricted Stock Unit
Shares / value
0
Estimated value
Report date
01 Jun 2023
Price
Ownership
Direct
Underlying class
Common Stock
Underlying amount
Form 4 holding President and CEO, Director

TCR2 THERAPEUTICS INC.

Security class
Stock Option (Right to Buy)
Shares / value
0
Estimated value
Report date
01 Jun 2023
Price
$0.7400
Ownership
Direct
Underlying class
Common Stock
Underlying amount

Insider Reports Filed by Garry E. Menzel

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .